News

2018

Unum Therapeutics 

September 17 2018 - Unum Therapeutics, today announced that the Company will be presenting data on the first dose level (40x106 ACTR+ T cells) of its ATTCK-20-03 clinical trial evaluating ACTR707 in combination with rituximab in patients with relapsed or refractory CD20-positive B cell non-Hodgkin Lymphoma (r/r NHL). 

View PDF 

 

Fulcrum Therapeutics 

September 5 2018 - Fulcrum Therapeutics, announced the closing of an $80 million Series B financing. Proceeds from the financing will be used to advance Fulcrum’s lead program in facioscapulohumeral muscular dystrophy (FSHD) into clinical testing, and to progress its pipeline of therapeutics for rare, genetically based neuromuscular, central nervous system and hematologic disorders.

View PDF 

 

Evidation Health 

August 23 2018 - Evidation Health, announced today a new technology partnership with Tidepool, an open source, not-for-profit company focused on making diabetes data more accessible, actionable and meaningful for people with diabetes, their care teams and researchers.

View PDF 

 

Ovid Therapeutics 

August 16 2018 - Ovid Therapeutics announces Phase 2 STARS Topline Data Accepted for Presentation at American Academy of Child and Adolescent Psychiatry Annual Meeting

View PDF 

 

Unum Therapeutics

August 13, 2018 - Unum Therapeutics today announced that an investigational new drug (IND) application is now active for ACTR T cells in combination with Trastuzumab for the treatment of patients with HER2+ advanced cancers

View PDF 

 

Unum Therapeutics

August 13, 2018 -Unum Therapeutics today reported financial results and provided a corporate update for the second quarter ended June 30, 2018 and recent activities

View PDF 

 

Ovid Therapeutics

August 6, 2018 - Ovid Therapeutics Announces Positive Topline Data from Phase 2 STARS Trial of OV101 for the Treatment of Angelman Syndrome

View PDF 

 

Navitor Pharmaceuticals

August 2, 2018 - Navitor Pharmaceuticals Appoints Thomas E. Hughes, Ph.D. as Chief Executive Officer

View PDF 

 

Evidation Health

August 1, 2018 - Evidation Health Announces $30M in New Funding

View PDF 

 

NeuroVia

July 25, 2018 - NeuroVia Initiates Phase 1/2 Trial of NV1205 for Treating Childhood Cerebral Adrenoleukodystrophy (CCALD)

View PDF 

 

Click Therapeutics

July 23, 2018 - Sanofi Ventures Leads $17 Million Financing of Click Therapeutics

View PDF 

 

Inozyme Pharma

July 17, 2018 - Inozyme Pharma Receives Orphan Drug Designation for INZ-701 in the United States and European Union

View PDF 

 

Ovid Therapeutics

July 11, 2018 - Ovid Therapeutics Announces Initiation of Phase 2 ROCKET Clinical Trial to Evaluate OV101 in Fragile X Syndrome

View PDF 

  

Sanofi Ventures

July 10, 2018 - Sanofi Doubles its Participation in Two Funds Dedicated to Innovation

View PDF 

  

Navitor Pharmaceuticals

June 26, 2018 - Navitor Pharmaceuticals Initiates a Clinical Study of NV‐5138, a Novel, Oral Small Molecule for Treatment‐Resistant Depression

View PDF 

 

Unum Therapeutics

June 25, 2018 - Unum Therapeutics Joins Russell 3000 Index

View PDF 

 

Immune Design

June 25, 2018 - Immune Design Presents Data on the Mechanism of Action of G100 via TLR4 Expressed in B Cell
Malignancies at the Inaugural AACR International Meeting Advances in Malignant Lymphoma

View PDF 

 

Omada Health

June 20, 2018 - Omada Health Adds New Programs for Type 2 Diabetes and Hypertension Self-Management

View PDF 

 

 

Inozyme Pharma

June 13, 2018 - Inozyme Pharma Offers No-Cost Genetic Testing for Rare Calcification Disorders

View PDF 

 

 

Science 37

May 31, 2018 - Sanofi Ventures Portfolio Company Science 37 is Ranked as Entrepreneur's Top 20 Companies to Watch for 2018

Link

 

 

Immune Design

May 24, 2018 - Immune Design Announces Launch of Web Portal for SYNOVATE Phase 3 Study of CMB305 Immunotherapy in Synovial Sarcoma

View PDF 

 

 

Unum Therapeutics

May 14, 2018 - Unum Therapeutics Reports First Quarter 2018 Financial Results and Provides Business Update

View PDF 

 

 

Ovid Therapeutics

May 8, 2018 - Ovid Therapeutics Reports First Quarter 2018 Financial Results and Corporate Progress

View PDF 

 

 

Immune Design

May 2, 2018 - Immune Design Reports First Quarter 2018 Financial Results and Provides Corporate Update

View PDF 

 

 

Common Sensing

April 11, 2018 - Common Sensing Secures $6.6M Series A Investment Round to Support Injectable Medicines

View PDF 

 

 

Unum Therapeutics

April 3, 2018 - Unum Therapeutics Announces Closing of Initial Public Offering and Concurrent Private Placement with Seattle Genetics

View PDF 

 

 

Immune Design

March 12, 2018 - Immune Design Reports Data Update for Lead Immunotherapy Programs: Improvement in Survival for CMB305 Monotherapy in Sarcoma and Increased Objective Responses for G100/pembrolizumab Combination in Follicular Lymphoma

View PDF 

 

 

Expansion Therapeutics

January 3, 2018 - Expansion Therapeutics Raises $55.3 Million in Series A Financing to Advance Portfolio of Novel RNA Targeted Small Molecule Medicines to Treat Rare Diseases  

View PDF 

 

2017

Ovid Therapeutics

December 20, 2017 - Ovid Therapeutics Announces TAK-935/OV935 Granted Orphan Drug Designation by U.S. FDA for Treatment of Lennox-Gastaut Syndrome

View PDF 

 

 

Ovid Therapeutics

December 19, 2017 - Ovid Therapeutics Announces OV101 Granted Fast Track Designation by U.S. FDA for Treatment of Angelman Syndrome

View PDF 

 

 

Curisium

December 14, 2017 - Curisium Raises $3.5M to Scale Innovative Healthcare Contracting on Blockchain

View PDF 

 

Ovid Therapeutics

December 5, 2017 - Ovid Therapeutics Announces TAK-935/OV935 Has Received Orphan Drug Designation from U.S. FDA for Treatment of Dravet Syndrome

View PDF 

 

Ovid Therapeutics

December 3, 2017 - Ovid Therapeutics Presents New Data Demonstrating Potential of TAK-935/OV935 as a Novel Treatment for Developmental and Epileptic Encephalopathies at the American Epilepsy Society (AES) Annual Meeting

View PDF 

 

Ovid Therapeutics

November 28, 2017 - Ovid Therapeutics Announces OV101 Shows Comparable PK Profile in Phase 1 Study of Adolescent Patients and Amends Phase 2 STARS Clinical Trial Protocol to Include Adolescents

View PDF 

 

Inozyme Pharma

November 15, 2017 - Inozyme Pharma Raises $49 Million in a Series A Financing to Develop Therapies for Rare Diseases Affecting Soft Tissues and Bone

View PDF 

 

Immune Design

October 19, 2017 - Immune Design Announces G100’s Receipt of Orphan Drug Designation by the EMA for the Treatment of Follicular Non-Hodgkin’s Lymphoma

View PDF 

 

Ovid Therapeutics

October 16, 2017 - Ovid Therapeutics Announces Positive Preclinical OV101 Data Demonstrating Behavioral Improvements in Fragile X Syndrome Model

View PDF 

 

Immune Design

October 16, 2017 - Immune Design Announces Positive FDA Feedback on Phase 3 Clinical Trial Design for CMB305 in Synovial Sarcoma Patients

View PDF 

 

Ovid Therapeutics

October 5, 2017 - Ovid Therapeutics to Present Preclinical Data Demonstrating OV101 Normalizes Behavioral Abnormalities at the 18th International Fragile X and Related Neurodevelopmental Disorders Workshop

View PDF 

  

Immune Design

September 8, 2017 - New Randomized Data From CMB305 + Checkpoint Inhibitor Study Demonstrate Greater Clinical Benefit and Immune Response

View PDF 

 

Ovid Therapeutics

September 6, 2017 - Ovid Therapeutics Appoints Ana C. Ward as Senior Vice President and General Counsel

View PDF 

 

Immune Design

August 30, 2017 - Immune Design Announces New CMB305 + Checkpoint Inhibitor Topline Data from an Upcoming Presentation at the ESMO 2017 Congress

View PDF 

 

Ovid Therapeutics

August 21, 2017 - Ovid Therapeutics Announces First Patient Randomized in Phase 1b/2a Clinical Trial of TAK-935/OV935 in Adults with Rare Epilepsies

View PDF 

 

Ovid Therapeutics

August 10, 2017 - Ovid Therapeutics Reports Second Quarter 2017 Financial Results and Corporate Progress

View PDF 

 

Evidation Health

July 31, 2017 - Sanofi Strengthens Ties with Evidation Health, Leader in Quantifying Health Behaviors

View PDF 

 

NeuroVia

July 20, 2017 - NeuroVia Closes Series A Financing Round of $14M to Develop Novel Treatment Option for X-ALD Disease

View PDF 

 

Ovid Therapeutics

June 23, 2017 - Ovid Therapeutics to be Added to Russell 2000®, 3000® and Microcap® Indexes

View PDF 

 

Omada Health

June 14, 2017 - Omada Health Raises $50 Million, Led by Cigna

View PDF 

 

Ovid Therapeutics

June 13, 2017 - Ovid Therapeutics Reports First Quarter 2017 Financial Results and Recent Corporate Progress

View PDF 

 

Immune Design

May 17, 2017 - Immune Design Reports First Quarter 2017 Financial Results and Provides Corporate Update

View PDF 

 

Immune Design

May 17, 2017 - New Clinical and Biomarker Data Validate Immune Design's Lead Programs and Discovery Platforms

View PDF 

 

Evidation Health

April 27, 2017 - Evidation Health secures Financing from Sanofi-Genzyme BioVentures to Fuel Commercial Growth

View PDF 

 

Science 37

April 25, 2017 - Science 37 Raises $29M To Bring Clinical Trials Directly Into Patients' Homes

View PDF

 

Ovid Therapeutics

April 10, 2017 - Ovid Therapeutics Announces Initiation of Phase 1 Clinical Trial of OV101 for Adolescents with Angelman Syndrome or Fragile X Syndrome

View PDF

 

GlycoMimetrics

March 7, 2017 - GlycoMimetrics Completes Enrollment of Newly Diagnosed AML Patient Cohort in Phase 2 Clinical Trial of GMI-1271

View PDF

 

Science 37

March 1, 2017 - Science 37 and Sanofi Introduce a New Partnership

View PDF

 

Immune Design

March 7, 2017 - Immune Design Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Corporate Update.

View PDF

 

Immune Design

March 1, 2017 - Immune Design To Present New Tumor Eradication Data for Systemic Plus Intratumoral Immunization at AACR Annual Meeting 2017.

View PDF

 

Immune Design

February 22, 2017 - Immune Design Receives Orphan Drug Designation for G100 Intratumoral Product Candidate

View PDF

 

Ovid Therapeutics

February 9, 2017 - Ovid Therapeutics Announces First Patient Randomized in the Phase 2 STARS Clinical Trial in Adults with Angelman Syndrome

View PDF

 

Ovid Therapeutics

February 9, 2017 - Ovid Therapeutics and NeuroPointDX Announce Collaboration to Identify Biomarkers for Angelman

View PDF

 

Ovid Therapeutics

January 19, 2017 - Ovid Therapeutics Names Jacqueline A. French, M.D. to Scientific Advisory Board

View PDF

 

Ovid Therapeutics

January 18, 2017 - Takeda and Ovid Therapeutics Announce Innovative Clinical Development and Commercialization Collaboration for TAK-935 in Rare Pediatric Epilepsies

View PDF

 

Lysosomal Therapeutics

January 9, 2017 - Allergan Enters Parkinson's Disease Through Option Arrangement with Lysosomal Therapeutics Inc. (LTI) for its Potential First-in-Class Breakthrough Compounds

View PDF